Published on : May 18, 2017
Albany, New York, May 18, 2017: Unhygienic conditions and infected medical equipment can cause Pseudomonas aeruginosa infections in an individual. The rising awareness towards this infection has directly affected the pipeline development of its treatment drug. To offer more insight into the pipeline review of the discussed infection an in-depth analysis is offered by Market Research Hub (MRH), which has been added to its vast repository. The research study has been detailed in the report titled as “Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2017”. The research report provides an overview of the Resistant Pseudomonas aeruginosa Infections (Infectious Disease) and its pipeline therapeutic development & assessment.
Pseudomonas aeruginosa is a major cause of infection, especially in patients with compromised host defense mechanisms. However, it is not a major cause for healthy individuals. The infection has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers and headache with risk factors such as age and weakened the immune system.
Firstly, the report starts with the overview of Resistant Pseudomonas aeruginosa infections and its therapeutic development. Under the therapeutic development, the pipeline overview, pipeline companies, pipeline universities/institutes and pipeline products under development are detailed. Further, the study provides the therapeutic assessment of the infections, which assess the target, mechanism of action, route of administration and molecule type.
Secondly, the companies involved in the therapeutics development of Resistant Pseudomonas aeruginosa infections are listed which include, Achaogen Inc., Biolytics Pharma, LegoChem Biosciences Inc., Melinta Therapeutics Inc. and Shionogi & Co Ltd. The drugs related to Pseudomonas aeruginosa Infections are also profiled with product description, mechanism of action and R&D progress. The drugs listed in the report are Biologic for multi-drug Resistant Pseudomonas aeruginosa infections, Biologic for Pseudomonas aeruginosa infection, Biologic for Resistant Pseudomonas aeruginosa infections, Cefiderocol, CSA-13, G-10, IMT-504, LCB-100200, Monoclonal Antibodies for Gram-Negative Bacterial infections, Monoclonal Antibody to Inhibit PcrV for Resistant Pseudomonas aeruginosa infections, RXP-873, Small Molecules for Resistant Pseudomonas aeruginosa infections, Small Molecules to Inhibit LpxC for Gram Negative Bacterial infections, and Small Molecules to Inhibit LpxC for Gram-Negative Bacterial infections and respiratory diseases.
Click here to get more info with TOC in a PDF Format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068026
Thirdly, the dormant projects of Resistant Pseudomonas aeruginosa infections are described. The report is a detailed analysis that is proofed with primary, secondary research and validated by an expert panel. The report also comprise of tables and figures that provide the pictorial representation of the details described in the provided researched report and thus assist in easy analysis.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-866-997-4948US Toll Free
Email : firstname.lastname@example.org